May 1- Momenta Pharmaceuticals Inc:. *Canaccord Genuity raises target price to $13 from $12; rating hold. Reuters Station users, click. 1568.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
TheStreet.com offers up 13 biotech predictions for 2013.